JP2008525008A - 髄膜炎菌に対するワクチン - Google Patents
髄膜炎菌に対するワクチン Download PDFInfo
- Publication number
- JP2008525008A JP2008525008A JP2007547670A JP2007547670A JP2008525008A JP 2008525008 A JP2008525008 A JP 2008525008A JP 2007547670 A JP2007547670 A JP 2007547670A JP 2007547670 A JP2007547670 A JP 2007547670A JP 2008525008 A JP2008525008 A JP 2008525008A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- dna
- antigen
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 241000588650 Neisseria meningitidis Species 0.000 title claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 claims abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 239000012634 fragment Substances 0.000 claims abstract description 26
- 230000004927 fusion Effects 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 238000002255 vaccination Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 69
- 108091007433 antigens Proteins 0.000 description 55
- 102000036639 antigens Human genes 0.000 description 55
- 239000000427 antigen Substances 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 31
- 238000010448 genetic screening Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 17
- 244000005700 microbiome Species 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000002147 killing effect Effects 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- -1 NMB0808 Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108010060123 Conjugate Vaccines Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940031670 conjugate vaccine Drugs 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 208000031729 Bacteremia Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000034762 Meningococcal Infections Diseases 0.000 description 4
- 101100051876 Neisseria meningitidis serogroup B (strain MC58) NMB0738 gene Proteins 0.000 description 4
- 101100541525 Neisseria meningitidis serogroup B (strain MC58) NMB1333 gene Proteins 0.000 description 4
- 101100055424 Neisseria meningitidis serogroup B (strain MC58) amgK gene Proteins 0.000 description 4
- 101100055601 Neisseria meningitidis serogroup B (strain MC58) anmK gene Proteins 0.000 description 4
- 101100072470 Neisseria meningitidis serogroup B (strain MC58) ilvC gene Proteins 0.000 description 4
- 101100399035 Neisseria meningitidis serogroup B (strain MC58) leuC gene Proteins 0.000 description 4
- 101100472531 Neisseria meningitidis serogroup B (strain MC58) rmuC gene Proteins 0.000 description 4
- 101100094058 Neisseria meningitidis serogroup B (strain MC58) rpsI gene Proteins 0.000 description 4
- 101100539640 Neisseria meningitidis serogroup B (strain MC58) upp gene Proteins 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000037941 meningococcal disease Diseases 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 3
- 101100395196 Neisseria meningitidis serogroup B (strain MC58) hisB gene Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000054767 gene variant Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010027280 Meningococcal sepsis Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150099894 GDHA gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 101100277701 Halobacterium salinarum gdhX gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000604168 Homo sapiens Neuromedin-B Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101100392454 Picrophilus torridus (strain ATCC 700027 / DSM 9790 / JCM 10055 / NBRC 100828) gdh2 gene Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 101100116769 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) gdhA-2 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 101150107671 hisB gene Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 101150068263 putA gene Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150001839 rsuA gene Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000034215 susceptibility to 1 bacteremia Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 101150076274 upp gene Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2004/005441 WO2005060995A2 (fr) | 2003-12-23 | 2004-12-23 | Vaccins |
| PCT/GB2005/005113 WO2006067518A2 (fr) | 2004-12-23 | 2005-12-23 | Vaccins et leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008525008A true JP2008525008A (ja) | 2008-07-17 |
Family
ID=36282716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547670A Pending JP2008525008A (ja) | 2004-12-23 | 2005-12-23 | 髄膜炎菌に対するワクチン |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1848457A2 (fr) |
| JP (1) | JP2008525008A (fr) |
| KR (1) | KR20070094762A (fr) |
| CN (2) | CN101115502A (fr) |
| AU (1) | AU2005317835A1 (fr) |
| CA (1) | CA2592156A1 (fr) |
| MX (1) | MX2007007886A (fr) |
| NO (1) | NO20073256L (fr) |
| RU (1) | RU2007127921A (fr) |
| WO (1) | WO2006067518A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006328153A1 (en) * | 2005-12-23 | 2007-06-28 | Imperial Innovations Limited | Neisseria meningitidis vaccines and their use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9814902D0 (en) * | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
-
2005
- 2005-12-23 RU RU2007127921/13A patent/RU2007127921A/ru not_active Application Discontinuation
- 2005-12-23 KR KR1020077015481A patent/KR20070094762A/ko not_active Application Discontinuation
- 2005-12-23 JP JP2007547670A patent/JP2008525008A/ja active Pending
- 2005-12-23 AU AU2005317835A patent/AU2005317835A1/en not_active Abandoned
- 2005-12-23 EP EP05823115A patent/EP1848457A2/fr not_active Withdrawn
- 2005-12-23 CA CA002592156A patent/CA2592156A1/fr not_active Abandoned
- 2005-12-23 MX MX2007007886A patent/MX2007007886A/es unknown
- 2005-12-23 CN CNA2005800479621A patent/CN101115502A/zh active Pending
- 2005-12-23 WO PCT/GB2005/005113 patent/WO2006067518A2/fr active Application Filing
-
2006
- 2006-12-21 CN CNA2006800516894A patent/CN101370514A/zh active Pending
-
2007
- 2007-06-25 NO NO20073256A patent/NO20073256L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007007886A (es) | 2008-01-16 |
| CN101370514A (zh) | 2009-02-18 |
| KR20070094762A (ko) | 2007-09-21 |
| WO2006067518A2 (fr) | 2006-06-29 |
| WO2006067518A3 (fr) | 2006-11-23 |
| NO20073256L (no) | 2007-09-17 |
| EP1848457A2 (fr) | 2007-10-31 |
| CA2592156A1 (fr) | 2006-06-29 |
| CN101115502A (zh) | 2008-01-30 |
| AU2005317835A1 (en) | 2006-06-29 |
| RU2007127921A (ru) | 2009-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836425A (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
| KR20080080069A (ko) | 독성 유전자, 단백질, 및 그 용도 | |
| PL197449B1 (pl) | Wyizolowane polipeptydy, immunogenne fragmenty tych polipeptydów, wyizolowane polinukleotydy, wektor ekspresyjny, komórka gospodarza zawierająca taki wektor, sposób wytwarzania polipeptydu, sposób ekspresji polinukleotydu, kompozycja szczepionki, przeciwciało immunospecyficzne w stosunku do polipeptydu lub jego immunogennego fragmentu, sposób diagnozowania zakażenia Neisseria meningitidis, zastosowania kompozycji zawierającej polipeptyd lub jego immunogenny fragment, lub polinukleotyd i kompozycja terapeutyczna do leczenia choroby wywołanej przez Neisseria meningitidis | |
| JP2011062203A (ja) | ビルレンス関連付着因子 | |
| Blake et al. | Vaccines for gonorrhea: where are we on the curve? | |
| DE69928925T2 (de) | Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper | |
| DE69918446T2 (de) | Polynucleotide and polypeptide basb033 aus neisseria meningitidis und ihre verwendungen | |
| CN101248084B (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
| JP2008525008A (ja) | 髄膜炎菌に対するワクチン | |
| JP2009520491A (ja) | 髄膜炎菌に対するワクチン | |
| RU2335505C2 (ru) | Белок nmb0928 и его применение в фармацевтических композициях | |
| US20080138357A1 (en) | Vaccines Against Neisseria Meningitidis | |
| JP2007517505A (ja) | 挿入変異体ライブラリーを血清でスクリーニングすることによる、抗原的に重要な髄膜炎菌抗原の同定 | |
| JP2004534524A (ja) | 病原性および共生ワクチン抗原 | |
| US20090208521A1 (en) | Pharmaceutical compositions containing protein nma0939 | |
| Lambert | Identification and Description of Burkholderia pseudomallei Proteins that Bind Host Complement-Regulatory Proteins via in silico and in vitro Analyses | |
| RU2336900C2 (ru) | Белок nmb1125 и его применение в фармацевтических композициях | |
| KR20080108576A (ko) | Ｎｍｂ0606 단백질을 포함하는 약학적 조성물 |